Literature DB >> 12072679

Catheter replacement in continuous arteriovenous hemodiafiltration: the balance between infectious and mechanical complications.

J P J Wester1, E J P de Koning, A B M Geers, H H Vincent, B M de Jongh, M Tersmette, J A Leusink.   

Abstract

OBJECTIVE: To assess the optimal moment of central vascular catheter replacement balancing infectious and mechanical complications in continuous renal replacement therapies in critically ill patients with acute renal failure.
METHODS: Prospective sequential trial with historical controls to compare liberal catheter replacement when clinically indicated with routine catheter replacement every 5 days in consecutive patients treated by continuous arteriovenous hemodiafiltration in a level I secondary referral intensive care unit of a university-affiliated teaching hospital. Intention-to-treat analysis.
MEASUREMENTS AND MAIN RESULTS: Twenty-two patients underwent catheter replacement when clinically indicated (group II), and 21 patients served as historical controls (group I). The groups were comparable for sex, age, Acute Physiology and Chronic Health Evaluation II scores, comorbidity, and creatinin and urea levels at the start of continuous arteriovenous hemodiafiltration. In group I, 71 catheters were used for 346 treatment days, and in group II, 68 catheters were used for 495 treatment days. The mean duration of catheterization was 4.9 +/- 2.0 days vs. 7.3 +/- 4.5 days, respectively (Student's t-test p <.001). There was no significant difference between the incidence of colonization of catheters (46.8% in group I vs. 39.1% in group II; chi-square p =.35) In group I, bacteremia and catheter sepsis occurred in two patients, whereas this did not occur in group II. The occurrence of mechanical complications was comparable in both groups (15.5% in group I vs. 19.1% in group II). There were significantly more mechanical complications with arterial vs. venous catheters (17 vs. 7; chi-square p =.027).
CONCLUSION: When catheters were changed as clinically indicated, they remained significantly longer in situ vs. being replaced routinely every 5 days; infectious and mechanical complications were comparable. The incidence of catheter sepsis was low (2.2%), and no prosthesis infection occurred. Catheter replacement when clinically indicated seems to be as safe as routine replacement every 5 days.

Entities:  

Mesh:

Year:  2002        PMID: 12072679     DOI: 10.1097/00003246-200206000-00017

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  5 in total

1.  Quasi-experimental study of sodium citrate locks and the risk of acute hemodialysis catheter infection among critically ill patients.

Authors:  Jean-Jacques Parienti; Stéphanie Deryckère; Bruno Mégarbane; Xavier Valette; Amélie Seguin; Bertrand Sauneuf; Jean-Paul Mira; Bertrand Souweine; Vincent Cattoir; Cédric Daubin; Damien du Cheyron
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

2.  Indwelling time and risk of infection of dialysis catheters in critically ill cancer patients.

Authors:  Abbas Harb; Georges Estphan; Gérard Nitenberg; Elisabeth Chachaty; Bruno Raynard; François Blot
Journal:  Intensive Care Med       Date:  2005-04-16       Impact factor: 17.440

3.  Continuous renal replacement therapy may increase the risk of catheter infection.

Authors:  Jean-Jacques Parienti; Audrey E Dugué; Claire Daurel; Jean-Paul Mira; Bruno Mégarbane; Leonard A Mermel; Cédric Daubin; Damien du Cheyron
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-17       Impact factor: 8.237

4.  Thrombosis and hemorrhage in heparin-induced thrombocytopenia in seriously ill patients.

Authors:  Jos P J Wester; Fred J L M Haas; Douwe H Biesma; J A Leusink; Gerda Veth
Journal:  Intensive Care Med       Date:  2004-05-20       Impact factor: 17.440

5.  How to deal with dialysis catheters in the ICU setting.

Authors:  Natacha Mrozek; Alexandre Lautrette; Jean-François Timsit; Bertrand Souweine
Journal:  Ann Intensive Care       Date:  2012-11-23       Impact factor: 6.925

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.